Pharmaceutical Stocks Face Big Challenges, But These 2 Could Survive the Storm

Overview of Patent Cliffs in the Pharmaceutical Industry

Pharmaceutical companies often face significant challenges due to patent cliffs, which occur when a drug's patent expires, allowing cheaper generic or biosimilar alternatives to enter the market. This can lead to a sharp decline in sales and market share for the original drugmaker. However, some companies are better equipped to handle these challenges thanks to their strong product pipelines, diversified portfolios, and innovative capabilities.

Two such companies that have faced or will soon face patent expiration for key products are Johnson & Johnson and Novartis. Despite these headwinds, both firms continue to demonstrate resilience and financial strength, making them attractive options for investors.

Johnson & Johnson: Navigating the Stelara Patent Cliff

In July 2024, Johnson & Johnson (NYSE: JNJ) began facing biosimilar competition for Stelara, one of its top-selling immunology drugs, in Europe. The U.S. followed suit in February of this year. As a result, Stelara’s sales have dropped significantly, with revenue falling by 42.7% in the second quarter compared to the same period last year, reaching $1.7 billion.

Despite this setback, Johnson & Johnson continues to post solid financial results. Its total revenue for the quarter reached $23.7 billion, representing a 5.8% increase year over year. The company has also raised its guidance for both top- and bottom-line performance for the year, showing confidence in its long-term outlook.

Johnson & Johnson’s diverse business model, which includes a wide range of pharmaceuticals and medical devices, helps mitigate the impact of patent cliffs. Key growth drivers include cancer treatments like Darzalex and Erleada, as well as Remicade, used for various immunology conditions. The company also recently launched Imaavy for myasthenia gravis and is awaiting regulatory approval for TAR-200, an investigational treatment for bladder cancer.

Additionally, Johnson & Johnson is a leader in the medical device sector, with its robotic-assisted surgery system, Ottava, currently undergoing clinical trials in the U.S. The company’s ability to innovate and adapt ensures it can manage future patent cliffs effectively.

As a dividend-paying stock, Johnson & Johnson has a long history of increasing payouts, having done so for 62 consecutive years. This makes it a reliable choice for income-focused investors.

Novartis: Preparing for Entresto’s Patent Expiration

Novartis (NYSE: NVS) is set to face generic competition for Entresto, a heart failure medication, later this year in the U.S. Through the first half of 2025, Entresto generated $4.6 billion in sales, with nearly 52% of that coming from the U.S. market. While the loss of patent exclusivity could threaten its revenue, Novartis remains confident in its ability to maintain high-single-digit revenue growth for the year.

The company’s broad portfolio of blockbuster drugs across multiple therapeutic areas provides a buffer against the impact of any single product’s patent expiration. Seven of its drugs generated more than $1 billion in revenue during the first six months of 2025, highlighting its strong market presence.

Novartis also has several new products in its pipeline that are expected to drive long-term growth. For example, Vanrafia, approved in April for treating proteinuria in patients with IgA nephropathy, is projected to reach peak sales of $1.5 billion. Additionally, the company is engaged in legal battles over the legitimacy of generic versions of Entresto, which could result in additional revenue if successful.

Even without these potential gains, Novartis is well-positioned to deliver consistent returns and annual dividend increases. It has raised its dividends for 28 consecutive years, making it a top choice for blue-chip dividend stocks.

Conclusion

Both Johnson & Johnson and Novartis demonstrate strong resilience in the face of patent cliffs. Their diversified product lines, innovative approaches, and commitment to shareholder returns make them compelling investments. Whether through new drug launches, strategic litigation, or continued financial performance, these companies are well-equipped to navigate the challenges of the pharmaceutical industry. Investors looking for stability and growth may find value in either of these industry leaders.